Form 4: PVCT CEO Acquires $35K Convertible Note

PROVECTUS BIOPHARMACEUTICALS CEO Edward Pershing acquired an 8% unsecured convertible promissory note valued at $35,000, convertible into Series D-1 Preferred Stock.

Summary

• CEO and Director Edward Pershing acquired an 8% unsecured convertible promissory note with a principal value of $35,000.
• The note is convertible into Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
• The note will automatically convert into Series D-1 Preferred Stock on September 18, 2026, or can be voluntarily converted earlier.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the company's common stock.
• The Series D-1 Preferred Stock will automatically convert into common stock on June 26, 2026, unless converted earlier.
• This transaction is part of the Issuer's 2025 Financing.
• Following this transaction, the reporting person beneficially owns 12,230 shares of Series D-1 Convertible Preferred Stock (underlying the note) and 0 derivative securities.

Sentiment

Score: 7

Explanation: The insider acquisition of a convertible note by the CEO is generally a positive signal of confidence, despite the potential for future dilution. It indicates management's belief in the company's value and successful capital raising.

Positives

• CEO Edward Pershing's acquisition of the convertible note demonstrates continued insider investment and confidence in the company's future prospects.
• The transaction is part of the company's 2025 Financing, indicating successful capital raising efforts.

Negatives

• The conversion of the note and preferred stock into common stock will result in dilution for existing common shareholders.
• The company is issuing debt (promissory note) which carries an 8% interest rate.

Risks

• Potential dilution of common stock ownership upon conversion of the Series D-1 Preferred Stock and the underlying promissory note.
• Future market conditions could impact the value of the common stock at the time of conversion, affecting the ultimate value of the investment.

Future Outlook

The promissory note is designed to convert into Series D-1 Preferred Stock by September 18, 2026, which will then automatically convert into common stock by June 26, 2026, unless earlier converted voluntarily.

Management Comments

• CEO Edward Pershing's acquisition of the convertible note signals his personal investment and confidence in the company's strategic direction and future prospects.

Industry Context

This insider transaction reflects a common financing strategy in the biopharmaceutical industry, where convertible debt and preferred stock are used to raise capital, often involving management participation to signal confidence to other investors.

Related Party Transactions

• CEO Edward Pershing's acquisition of the convertible promissory note from PROVECTUS BIOPHARMACEUTICALS, INC. constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential future dilution of common stock ownership upon conversion of the note and preferred stock.
• Company: Secures additional financing through the issuance of convertible debt, strengthening its capital structure.
• Management: CEO's personal investment aligns his interests further with shareholders.

Next Steps

• Voluntary or automatic conversion of the 8% Unsecured Convertible Promissory Note into Series D-1 Convertible Preferred Stock.
• Automatic conversion of Series D-1 Convertible Preferred Stock into Common Stock.

Key Dates

Keywords

PROVECTUS BIOPHARMACEUTICALS, PVCT, Edward Pershing, Insider Transaction, Form 4, Convertible Note, Series D-1 Preferred Stock, Common Stock, Financing, Biopharmaceutical, CEO, Director